| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IKZF1 |
| Uniprot No | Q13422 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-477aa |
| 氨基酸序列 | MDADEGQDMSQVSGKESPPVSDTPDEGDEPMPIPEDLSTTSGGQQSSKSDRVVASNVKVETQSDEENGRACEMNGEECAEDLRMLDASGEKMNGSHRDQGSSALSGVGGIRLPNGKLKCDICGIICIGPNVLMVHKRSHTGERPFQCNQCGASFTQKGNLLRHIKLHSGEKPFKCHLCNYACRRRDALTGHLRTHSVIKEETNHSEMAEDLCKIGSERSLVLDRLASNVAKRKSSMPQKFLGDKGLSDTPYDSSASYEKENEMMKSHVMDQAINNAINYLGAESLRPLVQTPPGGSEVVPVISPMYQLHKPLAEGTPRSNHSAQDSAVENLLLLSKAKLVPSEREASPSNSCQDSTDTESNNEEQRSGLIYLTNHIAPHARNGLSLKEEHRAYDLLRAASENSQDALRVVSTSGEQMKVYKCEHCRVLFLDHVMYTIHMGCHGFRDPFECNMCGYHSQDRYEFSSHITRGEHRFHMS |
| 预测分子量 | 56.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IKZF1重组蛋白的3篇参考文献的简要总结：
1. **《IKZF1 alterations in acute lymphoblastic leukemia: molecular mechanisms and therapeutic implications》**
- **作者**：Mullighan CG 等
- **摘要**：研究揭示了IKZF1基因的缺失或突变在B细胞急性淋巴细胞白血病(B-ALL)中的关键作用，指出IKZF1重组蛋白(如IK6突变体)通过破坏正常转录调控，导致白血病细胞增殖和化疗耐药性增强。
2. **《Structural basis of IKZF1 trimerization and its perturbation by oncogenic mutations》**
- **作者**：Sun L 等
- **摘要**：该文献通过结构生物学手段解析了IKZF1蛋白的锌指结构域，发现白血病相关的IKZF1重组蛋白(如截短型突变体)因失去关键结构域而无法形成功能性三聚体，进而影响其与DNA结合及抑癌功能。
3. **《CRISPR-Cas9 screening identifies IKZF1 as a critical regulator in T-cell acute lymphoblastic leukemia》**
- **作者**：Gianni F 等
- **摘要**：通过CRISPR筛选发现，IKZF1重组蛋白在T细胞急性淋巴细胞白血病(T-ALL)中异常表达，导致Notch信号通路异常激活，促进白血病细胞存活，提示靶向IKZF1可能成为潜在治疗策略。
IKZF1 (Ikaros Family Zinc Finger 1) is a critical transcription factor encoded by the *IKZF1* gene, primarily involved in hematopoietic development, particularly lymphopoiesis. As a member of the Ikaros zinc finger protein family, it regulates gene expression by binding to DNA through its N-terminal zinc finger domains, which mediate sequence-specific interactions, while its C-terminal domains facilitate protein-protein interactions and transcriptional repression or activation. IKZF1 plays a pivotal role in lymphoid cell differentiation, immune function, and tumor suppression by controlling cell cycle progression, chromatin remodeling, and lineage commitment.
Recombinant IKZF1 proteins are engineered to study its molecular mechanisms or develop therapeutic strategies. These proteins are typically produced in vitro using expression systems (e.g., *E. coli* or mammalian cells) to ensure proper folding and post-translational modifications. Researchers utilize recombinant IKZF1 to investigate its DNA-binding properties, interactions with co-factors like CK2 kinase or chromatin modifiers, and its role in diseases. For instance, *IKZF1* deletions or mutations are linked to B-cell acute lymphoblastic leukemia (B-ALL), where loss of IKZF1 function drives leukemogenesis by altering transcriptional programs. Recombinant variants, including truncated or phospho-mimetic forms, help dissect these pathological mechanisms.
Clinically, IKZF1-targeting therapies, such as immunomodulatory drugs (IMiDs; e.g., lenalidomide), leverage IKZF1 degradation to treat hematologic malignancies. Recombinant IKZF1 aids in screening such compounds or understanding resistance mechanisms. Additionally, its role in autoimmune diseases and immune checkpoint regulation underscores broader biomedical relevance. Despite advancements, challenges remain in deciphering context-dependent IKZF1 functions and optimizing therapeutic interventions, making recombinant protein studies indispensable for both basic and translational research.
×
